HHS Rolls Out Public Access Plans

The US Department of Health and Human Services outlines how the National Institutes of Health and its other agencies will make research results public.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, JOHN MARTINEZ PAVLIGAResponding to a February 2013 memorandum from John Holdren, director of the White House Office of Science and Technology Policy, the US Department of Health and Human Services (HHS) last week (February 27) announced its plans to expand public access to the research funded through its agencies, which include the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).

Building upon the existing requirement that publications authored by NIH-funded investigators be made publicly available within 12 months, implementation of HHS’s plan “will add . . . an estimated 110,000 peer-reviewed scholarly articles authored by HHS-funded researchers each year,” the agency noted in a statement.

Because the NIH, CDC, FDA, and other agencies operate independently of one another, HHS has issued separate public access action plans for each. Like the NIH, the CDC already has certain public access policies in place. The FDA, on the other hand, has no such existing rules.

“Our operating divisions are at different stages with respect to the maturity of their public access policies and infrastructure,” HHS Secretary Sylvia Burwell wrote in a February 27 letter. “We anticipate these policies ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies